BALTIMORE, MARYLAND, August 27, 2020 – For Immediate Release – Flavocure Biotech, Inc. (“Flavocure”) a drug discovery and development company, announced today the appointment of David Brooks, M.D., Ph.D. to serve as Interim Chief Medical Officer. Dr. Brooks will be responsible for the planning and execution of Flavocure’s planned clinical trials with Harvard Medical School and Dana Farber Cancer Institute.
“Flavocure is at a dynamic point of inflection, as we progress our Phase 1/2 study for human trials with our lead drug candidate, Caflanone™. Along with a patent issuance by the USPTO and an Orphan Drug designation by the FDA, we are preparing to enter the clinic.”
“Flavocure is at a dynamic point of inflection, as we progress our Phase 1/2 registration for human trials with our lead drug candidate, Caflanone™. This along with a patent issuance by the USPTO and an Orphan Drug designation by the FDA, we are preparing to enter the clinic ”, said CEO, Dr. Ngeh Toyang, Ph.D. “This is the right time to welcome David to the Flavocure team as he brings with him a wealth of knowledge in pharmaceutical development, commercialization, and depth of experience in a clinical setting.
Dr. Brooks will lend support to a growing team of talented researchers, medical doctors and scientists in Flavocure’s clinical group. Flavocure, VP of Regulatory and Quality, Dr. Tom Lang, who previously served as the President and Vice Chairman of Serono, Inc, and President of Stallergenes, Inc., said of the appointment, “Dr. Brooks is a well respected veteran of the biopharmaceutical industry and we are pleased to have him take on this leadership role in support of our clinical efforts.”
Dr. Brooks joins Flavocure having served as Vice President, Clinical Research and Translational Medicine for Deciphera Phamaceuticals. In this role, Dr. Brooks led the clinical development of four oncology product candidates, set clinical strategy for assets entering testing in direct anti-tumor and immune combination therapy, and planned clinical trials evaluating the combination of immunotherapies with novel myeloid cell checkpoint blockers. Prior to joining Deciphera, Dr. Brooks was Senior Director Physician, Oncology Early Clinical Development at AstraZeneca, where he led the clinical development of a dual specificity PI3K inhibitor across multiple oncology indications and managed external alliances and investigator-sponsored studies. Earlier in his career, Dr. Brooks served as Medical Head, Translational Medicine at TESARO Inc., as Chief Medical Officer and Senior Vice President at Generation Health, Inc., and as Medical Director, Global Clinical Medicine at Abraxis Bioscience, Inc. He also worked at Shire Human Genetic Therapies, Inc. and Merck & Co., Inc. Dr. Brooks holds a M.D. and Ph.D. in Molecular Biology from Cornell University. He completed his residency in Internal Medicine at the University of Pennsylvania and a fellowship in Medical Genetics at the Children’s Hospital of Philadelphia/Hospital of the University of Pennsylvania. He also served as an Instructor in Medicine in the Division of Medical Genetics at the University of Pennsylvania.
For his role with Flavocure, Dr. Brooks said, “Flavocure has developed a drug with the potential to change lives and the standard of care for patients. This is an exceptional moment in the evolution of immunotherapy and drugs like Caflanone.” He continued, “The Company’s lead drug has an outstanding safety profile and demonstrated tumor growth inhibition and prolongs survival of murine models of pancreatic cancer. I obviously share the enthusiasm to get the drug into the clinic and beyond”.
Flavocure Biotech, Inc. aims to be a leader in the transformation of medicinal properties from cannabis. The company, in collaboration with some of the most prestigious medical research institutions in the world, has discovered ground-breaking cannabis derived molecules and generated preliminary data indicating activity against therapeutically validated kinase mutation targets. Flavocure’s patent filed technology has led to an FDA Orphan Drug designation, as well as allowed the company to begin IND enabling studies for Phase 1/2 human clinical trials. Flavocure is currently privately held.
We seek safe harbor.